The National Biotechnology and Biomanufacturing Initiative, which channels more than $2 billion to America’s biotech sector, will have far-reaching implications not only for the domestic biotech space but industries at large, including life sciences. Where are the salient opportunities? What are the gravest risks? Check out the in-depth white paper from Randstad for answers.
view the white paper
